Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, et al. The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. Am J Pathol 2017;187(10):2139-51.
DOI: 10.1016/j.ajpath.2017.03.016
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16(21):5222-32.
DOI: 10.1158/1078-0432.CCR-10-1282
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res BCR. 2010;12(5):R68.
DOI: 10.1186/bcr2635
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121(7):2750-67.
DOI: 10.1172/JCI45014
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015;21(7):1688-98.
DOI: 10.1158/1078-0432.CCR-14-0432
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70.
DOI: 10.1038/nature11412
Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor- Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol 2016;2(10):1354-60.
DOI: 10.1001/jamaoncol.2016.1061
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2(4):361-70.
DOI: 10.1158/2326-6066.CIR-13-0127
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO- ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 2018;29(8):1634-57.
DOI: 10.1093/annonc/mdy192
Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol 2019;21(1):31-45.
DOI: 10.1007/s12094-018-02010-w
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24(5):628-37.
DOI: 10.1038/s41591-018-0009-7
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015;16(4):436-46.
DOI: 10.1016/S1470-2045(15)70064-1
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76.
DOI: 10.1056/NEJMoa072113
Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47.
DOI: 10.1200/JCO.2008.21.6457
Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60.
DOI: 10.1200/JCO.2010.28.0982
Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013;24(11):2773-80.
DOI: 10.1093/annonc/mdt276
Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(12):1351-60.
DOI: 10.1016/S1470-2045(14)70444-9
Garber HR, Litton JK. Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Curr Opin Oncol 2019;31(3):247-55.
DOI: 10.1097/CCO.0000000000000516
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377(6):523-33.
DOI: 10.1056/NEJMoa1706450
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018;379(8):753-63.
DOI: 10.1056/NEJMoa1802905
Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21(10):1269-82.
DOI: 10.1016/S1470-2045(20)30447-2
García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol 2016;10(Suppl 1):31-9.
DOI: 10.4137/CMO.S34540
Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol 2019;5(3):334-42.
DOI: 10.1001/jamaoncol.2018.5152
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(1):44-59.
DOI: 10.1016/S1470-2045(19)30689-8
Schneeweiss A, Rugo HS, Winer EP, Barrios CH, Iwata H, Dieras V, et al. IMpassion130: Expanded safety analysis from a Phase 3 study of atezolizumab (A) + nab- paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2019;37(15_suppl):1068-1068.
DOI: 10.1200/JCO.2019.37.15_suppl.1068
Miles D, Gligorov J, Andre F, et al. Primary results from IMpassion131, a double- blind, placebo-controlled, randomized phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 202;32(8):994-1004.
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double- blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828.
DOI: 10.1016/S0140-6736(20)32531-9
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022;387:217-26.
DOI: 10.1056/NEJMoa2202809
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017;18(10):1360-72.
DOI: 10.1016/S1470-2045(17)30450-3
Dent D, Kim S, Oliveira M, et al. Double-blind placebo-controlled randomized phase III trial evaluating first-line ipatasertib combined with paclitaxel for -PIK3CA/AKT1/PTEN- altered locally advanced unresectable or metastatic triple-negative breast cancer: Primary results from IPATunity130 Cohort A. San Antonio Breast Cancer Symposium. 2020 Abstract GS3-04.
DOI: 10.1158/1538-7445.SABCS20-GS3-04
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol 2020;38(5):423-33.
DOI: 10.1200/JCO.19.00368
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 22 de abril de 2021;384(16):1529-41.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 7 de julio de 2022;387(1):9-20.
Krop I, Juric D, T Shimizu, et al. Datopotamab deruxtecan in advanced/metastatic HER2 negative breast cancer: Triple negative breast cancer results from the phase 1 TROPION-PanTumor01 study. San Antonio Breast Cancer Symposium 2021. Abstract GS1- 05.
DOI: 10.1158/1538-7445.SABCS21-GS1-05
Número de descargas:
91587
Número de visitas:
2192
Citas:
0
